Homepage > Company > Media > Pharma News > 2024 > Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor

Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor

Chengdu Baiyu Pharmaceutical Co., Ltd. (Chengdu, China) announced that it has entered into an exclusive license agreement with Novartis for a small molecule anti-tumor asset.

Under the terms of the license agreement, Baiyu will receive an upfront payment of $70 million and is eligible to receive additional development, regulatory and commercial milestones payments of up to $1.1 billion, as well as tiered royalties.

Novartis has been granted an exclusive worldwide license for the development and commercialization of this asset. BFC Group acted as the exclusive financial advisor to Baiyu.

This collaboration is an important step for Baiyu in making potential anti-tumor drugs available to patients globally, and Baiyu look forward to positive results being realized.

About Chengdu Baiyu Biopharmaceutical Co., Ltd.

Founded in 2005, Baiyu is a pharmaceutical company headquartered in Chengdu, China. The company is dedicated to discover and develop innovative medicines, for which it has earned numerous prestigious national awards. With over 20 years of focused research on the core pharmacological components of Ginkgo biloba, we have successfully developed modern botanical drugs, including Ginkgolide Injection and Ginkgolide Dropping Pills.

Read also

Intercept’s liver disease drug Ocaliva faces FDA approval delay

An FDA AdCom in September recommended against full approval for Ocaliva (obeticholic acid) by a 13-1 vote for the treatment of primary biliary cholangitis. The original FDA full approval decis...

Rani Therapeutics shares hold buy rating on positive preclinical data

On Thursday, Rani Therapeutics Holdings Inc. shares maintained a positive outlook as H.C. Wainwright reaffirmed a Buy rating with a $9.00 price target.

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Sagimet Biosciences' Denifanstat shows significant potential in treating MASH, with FDA Breakthrough Therapy designation and peer-reviewed validation, supporting a "Strong Buy" rating. D...

Rectify Pharmaceuticals to Present New Preclinical Data at The American Association for the Study of Liver Diseases Annual Meeting

Rectify Pharmaceuticals, Inc., a biotechnology company developing positive functional modulators (PFMs), small molecule therapeutics that restore and enhance membrane protein function, today a...